ASCEND-ing results: acalabrutinib is well-tolerated and highly effective in R/R CLL 

Paolo Ghia, Università Vita-Salute San Raffaele, Milan, Italy, discusses the late-breaking abstract data on the ASCEND trial (NCT02970318) of acalabrutinib in previously treated chronic lymphocytic leukemia (CLL). This treatment was demonstrated to significantly prolong survival without disease progression, indicating that acalabrutinib has the potential to change current practice by providing a well-tolerated, highly effective BTK inhibitor treatment. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.